Moreover, Bufalin treatment led to a substantial decrease in cell invasiveness in HepG2 cells (Figure 5D), suggesting that the SRC‐1 inhibitor significantly attenuated HCC invasion in vitro. The gene discussed is SRC; the disease is hepatocellular carcinoma.